An oral drug study’s results are due Tuesday. Biomea Fusion will discuss them on a 4:30 p.m. webcast.
Alpha Vantage · Stock Titan · · AI-summarised by FinFlash
Biomea Fusion (Nasdaq: BMEA) is set to announce the results of its Phase I GLP-131 study for BMF-650, an investigational oral small-molecule GLP-1 receptor agonist, on Tuesday, October 13, 2026. The company will host a conference call and webcast at 4:30 p.m. ET (1:30 p.m. PT) on the same day to discuss these results.
Understand the context
Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.